FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2039-2049 May 8, 2008 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The current era of research in antiangiogenic therapy for cancer began in earnest in 1971 with the publication of Folkman's imaginative hypothesis,¹ but 33 years would elapse before the first drug developed as an inhibitor of angiogenesis was approved by the Food and Drug Administration (FDA).^2,3 This approval was based on the survival benefit observed in a randomized phase 3 trial of first-line treatment of metastatic colorectal cancer; in that trial, bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF), was combined with conventional chemotherapy.⁴ Bevacizumab therapy also increased overall survival in the first-line treatment of advanced . . . [Full Text of this Article]

The VEGF and VEGF-Receptor Family in Tumor Angiogenesis

The Notch–Deltalike Ligand 4 Signaling Pathway

Angiogenesis and Circulating Bone Marrow–Derived Cells

Resistance to Antiangiogenic Drugs

Angiogenesis and Cancer Stem Cells

Summary

Source Information

From the Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, and the Department of Medical Biophysics, University of Toronto — both in Toronto.

Address reprint requests to Dr. Kerbel at the Odette Cancer Centre, S-217, 2075 Bayview Ave., Toronto, ON M4N 3M5, Canada, or at robert.kerbel@sri.utoronto.ca.

Related Letters:

Tumor Angiogenesis
Zerbini G., Lorenzi M., Palini A., Kerbel R. S.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:763-764, Aug 14, 2008. Correspondence

This article has been cited by other articles:

• Matulonis, U. A., Berlin, S., Ivy, P., Tyburski, K., Krasner, C., Zarwan, C., Berkenblit, A., Campos, S., Horowitz, N., Cannistra, S. A., Lee, H., Lee, J., Roche, M., Hill, M., Whalen, C., Sullivan, L., Tran, C., Humphreys, B. D., Penson, R. T. (2009). Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer. JCO 27: 5601-5606 [Abstract] [Full Text]  
• Lee, S. L. C., Rouhi, P., Jensen, L. D., Zhang, D., Ji, H., Hauptmann, G., Ingham, P., Cao, Y. (2009). Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc. Natl. Acad. Sci. USA 106: 19485-19490 [Abstract] [Full Text]  
• Lee, S. M., Rudd, R., Woll, P. J., Ottensmeier, C., Gilligan, D., Price, A., Spiro, S., Gower, N., Jitlal, M., Hackshaw, A. (2009). Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer. JCO 27: 5248-5254 [Abstract] [Full Text]  
• Briasoulis, E., Pappas, P., Puozzo, C., Tolis, C., Fountzilas, G., Dafni, U., Marselos, M., Pavlidis, N. (2009). Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer. Clin. Cancer Res. 15: 6454-6461 [Abstract] [Full Text]  
• Hedlund, E.-M., Hosaka, K., Zhong, Z., Cao, R., Cao, Y. (2009). Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc. Natl. Acad. Sci. USA 106: 17505-17510 [Abstract] [Full Text]  
• Clapp, C., Thebault, S., Jeziorski, M. C., Martinez De La Escalera, G. (2009). Peptide Hormone Regulation of Angiogenesis. Physiol. Rev. 89: 1177-1215 [Abstract] [Full Text]  
• van Kruijsdijk, R. C.M., van der Wall, E., Visseren, F. L.J. (2009). Obesity and Cancer: The Role of Dysfunctional Adipose Tissue. Cancer Epidemiol. Biomarkers Prev. 18: 2569-2578 [Abstract] [Full Text]  
• Daenen, L. G., Shaked, Y., Man, S., Xu, P., Voest, E. E., Hoffman, R. M., Chaplin, D. J., Kerbel, R. S. (2009). Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Molecular Cancer Therapeutics 8: 2872-2881 [Abstract] [Full Text]  
• Marttila-Ichihara, F., Auvinen, K., Elima, K., Jalkanen, S., Salmi, M. (2009). Vascular Adhesion Protein-1 Enhances Tumor Growth by Supporting Recruitment of Gr-1+CD11b+ Myeloid Cells into Tumors. Cancer Res. 69: 7875-7883 [Abstract] [Full Text]  
• Carmi, Y., Voronov, E., Dotan, S., Lahat, N., Rahat, M. A., Fogel, M., Huszar, M., White, M. R., Dinarello, C. A., Apte, R. N. (2009). The Role of Macrophage-Derived IL-1 in Induction and Maintenance of Angiogenesis. J. Immunol. 183: 4705-4714 [Abstract] [Full Text]  
• Finetti, F., Donnini, S., Giachetti, A., Morbidelli, L., Ziche, M. (2009). Prostaglandin E2 Primes the Angiogenic Switch via a Synergic Interaction With the Fibroblast Growth Factor-2 Pathway. Circ. Res. 105: 657-666 [Abstract] [Full Text]  
• Hu, J., Dong, A., Fernandez-Ruiz, V., Shan, J., Kawa, M., Martinez-Anso, E., Prieto, J., Qian, C. (2009). Blockade of Wnt Signaling Inhibits Angiogenesis and Tumor Growth in Hepatocellular Carcinoma. Cancer Res. 69: 6951-6959 [Abstract] [Full Text]  
• Eng, C., Leone, G., Orloff, M. S., Ostrowski, M. C. (2009). Genomic Alterations in Tumor Stroma. Cancer Res. 69: 6759-6764 [Abstract] [Full Text]  
• Schneider, B. P., Radovich, M., Miller, K. D. (2009). The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer. Clin. Cancer Res. 15: 5297-5302 [Abstract] [Full Text]  
• Ebos, J. M. L., Lee, C. R., Kerbel, R. S. (2009). Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy. Clin. Cancer Res. 15: 5020-5025 [Abstract] [Full Text]  
• Lee, S. M., Woll, P. J., Rudd, R., Ferry, D., O'Brien, M., Middleton, G., Spiro, S., James, L., Ali, K., Jitlal, M., Hackshaw, A. (2009). Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. JNCI J Natl Cancer Inst 101: 1049-1057 [Abstract] [Full Text]  
• Ruegg, C., Peters, S. (2009). Thalidomide in Small Cell Lung Cancer: Wrong Drug or Wrong Disease?. JNCI J Natl Cancer Inst 101: 1034-1035 [Full Text]  
• Frentzen, A., Yu, Y. A., Chen, N., Zhang, Q., Weibel, S., Raab, V., Szalay, A. A. (2009). Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc. Natl. Acad. Sci. USA 106: 12915-12920 [Abstract] [Full Text]  
• Cullen, M., Seaman, S., Chaudhary, A., Yang, M. Y., Hilton, M. B., Logsdon, D., Haines, D. C., Tessarollo, L., St. Croix, B. (2009). Host-Derived Tumor Endothelial Marker 8 Promotes the Growth of Melanoma. Cancer Res. 69: 6021-6026 [Abstract] [Full Text]  
• Sun, H.-L., Tsai, A.-C., Pan, S.-L., Ding, Q., Yamaguchi, H., Lin, C.-N., Hung, M.-C., Teng, C.-M. (2009). EPOX Inhibits Angiogenesis by Degradation of Mcl-1 through ERK Inactivation. Clin. Cancer Res. 15: 4904-4914 [Abstract] [Full Text]  
• Pucci, F., Venneri, M. A., Biziato, D., Nonis, A., Moi, D., Sica, A., Di Serio, C., Naldini, L., De Palma, M. (2009). A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 114: 901-914 [Abstract] [Full Text]  
• McLarty, J., Bigelow, R. L.H., Smith, M., Elmajian, D., Ankem, M., Cardelli, J. A. (2009). Tea Polyphenols Decrease Serum Levels of Prostate-Specific Antigen, Hepatocyte Growth Factor, and Vascular Endothelial Growth Factor in Prostate Cancer Patients and Inhibit Production of Hepatocyte Growth Factor and Vascular Endothelial Growth Factor In vitro. Cancer Prevention Research 2: 673-682 [Abstract] [Full Text]  
• Sabatino, M., Kim-Schulze, S., Panelli, M. C., Stroncek, D., Wang, E., Taback, B., Kim, D. W., DeRaffele, G., Pos, Z., Marincola, F. M., Kaufman, H. L. (2009). Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy. JCO 27: 2645-2652 [Abstract] [Full Text]  
• Loges, S., Schmidt, T., Carmeliet, P. (2009). "Antimyeloangiogenic" Therapy for Cancer by Inhibiting PlGF. Clin. Cancer Res. 15: 3648-3653 [Abstract] [Full Text]  
• Chi, A. S., Sorensen, A. G., Jain, R. K., Batchelor, T. T. (2009). Angiogenesis as a Therapeutic Target in Malignant Gliomas. The Oncologist 14: 621-636 [Abstract] [Full Text]  
• Schoder, H., Fury, M., Lee, N., Kraus, D. (2009). PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma. JNM 50: 74S-88S [Abstract] [Full Text]  
• Shojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., Meng, Y. G., Ferrara, N. (2009). G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. USA 106: 6742-6747 [Abstract] [Full Text]  
• De Palma, M. (2009). Tissue-Specific Programming of Angiogenic Vasculature and Solid Tumor Development. aacredbook 2009: 153-157 [Full Text]  
• Horn, L., Sandler, A. B. (2009). Angiogenesis in the Treatment of Non-Small Cell Lung Cancer. Proc Am Thorac Soc 6: 206-217 [Abstract] [Full Text]  
• Zhong, C., Qu, X., Tan, M., Meng, Y. G., Ferrara, N. (2009). Characterization and Regulation of Bv8 in Human Blood Cells. Clin. Cancer Res. 15: 2675-2684 [Abstract] [Full Text]  
• Ruiz de Almodovar, C., Lambrechts, D., Mazzone, M., Carmeliet, P. (2009). Role and Therapeutic Potential of VEGF in the Nervous System. Physiol. Rev. 89: 607-648 [Abstract] [Full Text]  
• Smallridge, R. C, Marlow, L. A, Copland, J. A (2009). Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16: 17-44 [Abstract] [Full Text]  
• Wu, Z.-p., Gao, C.-w., Wu, Y.-g., Zhu, Q.-s., Yan Chen, , Xin Liu, , Chuen Liu, (2009). Inhibitive Effect of Artemether on Tumor Growth and Angiogenesis in the Rat C6 Orthotopic Brain Gliomas Model. Integr Cancer Ther 8: 88-92 [Abstract]  
• Gressett, S. M, Shah, S. R (2009). Intricacies of Bevacizumab-Induced Toxicities and Their Management. The Annals of Pharmacotherapy 43: 490-501 [Abstract] [Full Text]  
• Cao, Y. (2009). Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands. Sci Signal 2: re1-re1 [Abstract] [Full Text]  
• Helfrich, I., Edler, L., Sucker, A., Thomas, M., Christian, S., Schadendorf, D., Augustin, H. G. (2009). Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma. Clin. Cancer Res. 15: 1384-1392 [Abstract] [Full Text]  
• Pang, X., Yi, T., Yi, Z., Cho, S. G., Qu, W., Pinkaew, D., Fujise, K., Liu, M. (2009). Morelloflavone, a Biflavonoid, Inhibits Tumor Angiogenesis by Targeting Rho GTPases and Extracellular Signal-Regulated Kinase Signaling Pathways. Cancer Res. 69: 518-525 [Abstract] [Full Text]  
• Fish, J. E., Srivastava, D. (2009). MicroRNAs: Opening a New Vein in Angiogenesis Research. Sci Signal 2: pe1-pe1 [Abstract] [Full Text]  
• Wen, P. Y., Norden, A. D., Drappatz, J. (2009). Antiangiogenic Therapies for Malignant Gliomas. Am Soc Clin Oncol Ed Book 2009: 113-117 [Abstract] [Full Text]  
• Mattila, E., Auvinen, K., Salmi, M., Ivaska, J. (2008). The protein tyrosine phosphatase TCPTP controls VEGFR2 signalling. J. Cell Sci. 121: 3570-3580 [Abstract] [Full Text]  
• Keeley, E. C., Mehrad, B., Strieter, R. M. (2008). Chemokines as Mediators of Neovascularization. Arterioscler. Thromb. Vasc. Bio. 28: 1928-1936 [Abstract] [Full Text]  
• Zerbini, G., Lorenzi, M., Palini, A., Kerbel, R. S. (2008). Tumor Angiogenesis. NEJM 359: 763-764 [Full Text]